Trials / Completed
CompletedNCT05433337
Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management: An Extension Study
"PROSPER-FM-EXT": Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management: An Extension Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Swing Therapeutics, Inc. · Academic / Other
- Sex
- All
- Age
- 22 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed as a 9-month extension of the original study (PROSPER-FM). The purpose of the extension study is to assess the long-term (up to 1 year) response to a digital therapy in the treatment of fibromyalgia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Digital ACT | Study participants will continue to receive Digital Acceptance and Commitment Therapy in addition to their standard care for fibromyalgia |
Timeline
- Start date
- 2022-06-08
- Primary completion
- 2024-03-05
- Completion
- 2024-03-05
- First posted
- 2022-06-27
- Last updated
- 2024-06-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05433337. Inclusion in this directory is not an endorsement.